BSB News: May 26
This quarter has been an important one for Broken String. From our FDA Master File submission and commercial expansion into Southeast Asia, to the launch of our new brand and website, we’ve continued building towards a clear goal: helping therapy developers generate high-quality, genome-wide safety data earlier, faster, and in relevant cell systems.
In this issue:
FDA Master File (MAF) submission for INDUCE-seq®
A newly published study in Molecular Therapy Methods & Clinical Development
Our strategic rebrand & evolution
Strategic expansion into Southeast Asia
FDA guidance
New technical resources and educational content
Highlights from recent global events
Key highlights
1) FDA Master File submission:
We have officially submitted a Master File (MAF) to the U.S. Food and Drug Administration (FDA) for our proprietary INDUCE-seq® platform. This milestone drastically simplifies how our partners integrate gold-standard, genome-wide DNA break-mapping data into their Investigational New Drug (IND)-enabling studies.
2) A newly published study in Molecular Therapy Methods & Clinical Development:
The study explored CRISPR-Cas9 strategies for excising the C9orf72 repeat expansion associated with frontotemporal dementia (FTD) and ALS.
’’INDUCE-seq uniquely detected the true off-target site without requiring prior nomination and without identifying false positives, making it a more effective nomination method than both Cas-OFFinder and CHANGE-seq’’.
The study screened more than 120 dual-gRNA combinations in patient-derived iPSCs to identify the most efficient and safest editing strategies. Importantly, the authors found that computational predictions alone were not enough to identify the best-performing guide combinations and that empirical validation remained critical.
3) Our strategic rebrand & evolution:
On March 31st, we unveiled our complete strategic rebrand. This evolution reflects our transformation from a specialist technology provider into a commercially focused, comprehensive partner supporting therapeutic programs from early discovery through to clinical stages.
4) FDA Guidance
In April 2026, the FDA released critical new draft guidance for genome editing safety. In the document the FDA established what they expect for NGS-based off-target assessment in IND-enabling studies for gene therapy products.
Take a look at the advice flyer here
5) Global expansion into Southeast Asia:
We have officially appointed Sciencewerke Pte Ltd as our distributor across Singapore, Malaysia, Indonesia, Vietnam, and Thailand. This partnership brings INDUCE-seq® directly to regional life science and pharmaceutical sectors to accelerate clinical impact.
Featured resources
The all-new digital resource library
The new resources hub has been designed with users in mind. The searchable database is equipped with search and filtering tools. Whether you are looking for specific application notes, peer-reviewed data, or workflow overviews, you can pinpoint the exact resources that matter most to your research pipelines in seconds.
New resources include:
Technical note: Experimental design guidance
Poster: INDUCE-seq® Discovery Platform: High throughput, Comparative On- and Off-Target Analysis
Blog: Solving the Off-Target Analysis Bottleneck: Decision-Focused Bioinformatics for Gene Editing
Where have we been?
Our team has had an incredibly active few weeks on the road, sharing data, engaging with researchers, and discussing safety standardization across the global cell & gene therapy community
ELRIG Cell & Gene Therapy, Cambridge, UK:
It was great to spend time at ELRIG back in February, hearing so many inspiring discussions across the cell and gene therapy community.
From advances in delivery technologies to the growing focus on safety and genome-wide off-target detection, the talks reinforced how quickly the field is moving, and how important robust analytical tools are becoming as therapies move closer to the clinic.
A standout moment was watching our very own Senior Scientist, Eve Stalker present her poster on: “INDUCE-seq® Discovery Platform: High-throughput, comparative on- and off-target analysis.”
Advanced Therapies, London UK:
This was an excellent opportunity for our commercial and technical teams to engage directly with advanced medicinal developers.
The team had some fantastic conversations over the 2-day event, culminating in our very own Lucinda Lee presenting her talk entitled: 'From Causes to Consequences: Decoding Off-Target Events in CRISPR Gene Editing.'
ISCT 2026, Dublin, Ireland:
ISCT 2026 was a fantastic opportunity for the team to connect directly with the global cell and gene therapy community and continue conversations around genome-wide editing assessment in translational workflows.
Our team had some valuable discussions at the booth with researchers, therapy developers, and industry partners exploring how unbiased, cell-based approaches can support both early discovery decisions and later-stage IND-enabling studies. We also had the chance to establish a number of new connections across the international CGT community, which we are excited to continue building on throughout the year.
ASGCT 2026, Boston, USA
ASGCT 2026 provided an excellent platform for the team to share new data and engage in conversations around the evolving expectations for genome-wide off-target assessment in gene editing.
The team also presented the poster “Unbiased Genome-wide Assessment of Gene Editing-associated DNA Breaks in Therapeutically Relevant Cells Using INDUCE-seq®”, highlighting how INDUCE-seq® enables sensitive, genome-wide detection of DNA breaks across multiple editing modalities, including CRISPR nucleases and base editors.
The work demonstrated how efficacy and specificity can be profiled simultaneously in a single experiment, supporting both early guide screening and rigorous off-target characterization.
Upcoming Events
We are keeping the momentum going through the rest of the year. If you are attending any of the following global events, we would love to connect, to show our platform capabilities.
FASEB – Porto, Portugal | 6-9 July 2026
ISCT Asia 2026 - Singapore | 2-5 September 2026
7th Genome Editing Therapeutics Summit – Boston, MA, USA | 28–30 September 2026
Meeting on the Mesa 2026 - Phoenix, AZ, USA | 5–7 October 2026
ESGCT – Hamburg, Germany | 27–30 October 2026
More events we may attend are being added throughout the year, be sure to check our events page to see if we may be at an event near you!
Get in touch with our team
Ready to bring the gold standard of genome-wide off-target analysis into your own laboratory workflows? Send us a direct message here on LinkedIn or contact our team via the below channels!
Email us: [email protected] or get in touch via our form here.